{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:20Z","timestamp":1787023280055,"version":"build-2736575974"},"reference-count":150,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T00:00:00Z","timestamp":1331856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction.<\/jats:title>\n                    <jats:p>Folliculitis is the most common side effect of epidermal growth factor receptor (EGFR) inhibitors (EGFRIs). It is often apparent, altering patients' quality of life and possibly impacting compliance. Variations in terms of the treatment-related incidence and intensity have not been fully elucidated. Tetracyclines have been recommended for the prophylaxis and treatment of folliculitis but their efficacy is yet to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods.<\/jats:title>\n                    <jats:p>We carried out two systematic literature reviews. The first assessed the preventive and curative efficacy of tetracyclines. The second assessed the incidence of grade 3\u20134 folliculitis in the main clinical studies published.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>In four randomized studies, preventive tetracycline treatment was associated with a significantly lower incidence of grade 2\u20133 folliculitis and a better quality of life in three of the four studies. In curative terms, tetracycline efficacy was not evaluated in any randomized study, but an improvement in grade \u22652 folliculitis was reported in case series. The frequency and severity of folliculitis seem to be greater with the antibodies than with the tyrosine kinase inhibitors. Analysis restricted to lung cancer studies showed a statistically greater incidence in terms of grade 3\u20134 folliculitis with cetuximab (9%) and erlotinib (8%) than with gefitinib (2%) (p &amp;lt; .0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Unless contraindicated, a tetracycline should be routinely prescribed prophylactically for patients treated with an EGFRI (level of evidence, B2). In curative therapy, the level of evidence for tetracycline efficacy is low (level of evidence, D). The incidence of grade 3\u20134 folliculitis induced by EGFRIs appears to be lower with gefitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0365","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T00:52:11Z","timestamp":1331945531000},"page":"555-568","source":"Crossref","is-referenced-by-count":44,"title":["Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review"],"prefix":"10.1093","volume":"17","author":[{"given":"Jean-Baptiste","family":"Bachet","sequence":"first","affiliation":[{"name":"a Department of Hepato-Gastro-Enterology, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique - H\u00f4pitaux de Paris, Universit\u00e9 Pierre & Marie Curie (UPMC), Paris, France and GERCOR, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Peuvrel","sequence":"additional","affiliation":[{"name":"b Department of Dermatology-Oncology, CHU de Nantes, H\u00f4tel Dieu, Nantes, France and CIC Bioth\u00e9rapie INSERM 0305, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Bachmeyer","sequence":"additional","affiliation":[{"name":"c Department of Internal Medicine, H\u00f4pital Tenon, Assistance Publique - H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Reguiai","sequence":"additional","affiliation":[{"name":"d Department of Dermatology, CH Robert Debr\u00e9, Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre A.","family":"Gourraud","sequence":"additional","affiliation":[{"name":"e Methodomics Inc., Mortagne sur Sevre, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[{"name":"f Department of Hepato-Gastro-Enterology and Gastro-Intestinal Oncology, CHU Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[{"name":"g Centre R\u00e9gional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene J.","family":"Bensadoun","sequence":"additional","affiliation":[{"name":"h Radiation Oncology Department, Hospital and University, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[{"name":"b Department of Dermatology-Oncology, CHU de Nantes, H\u00f4tel Dieu, Nantes, France and CIC Bioth\u00e9rapie INSERM 0305, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"i Department of Medical Oncology, H\u00f4pital St. Antoine, Assistance Publique - H\u00f4pitaux de Paris, Universit\u00e9 Pierre & Marie Curie (UPMC), Paris, France and GERCOR, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,3,16]]},"reference":[{"key":"2021122308154462900_B1","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining?","volume":"23","author":"Per\u00e9z-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"2021122308154462900_B4","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B6","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"2021122308154462900_B7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab induced rash: Observations from 933 patients enrolled in North Central Cancer Treatment Group Study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"2021122308154462900_B11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B12","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","article-title":"Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study","volume":"26","author":"Wilke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"2021122308154462900_B15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2021122308154462900_B18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","article-title":"Skin toxicities of targeted therapies","volume":"45","author":"Segaert","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122308154462900_B19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122308154462900_B22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients","volume":"55","author":"Ro\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B24","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122308154462900_B25","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/cncr.24088","article-title":"Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy","volume":"115","author":"Peeters","year":"2009","journal-title":"Cancer"},{"issue":"suppl vii","key":"2021122308154462900_B26","first-page":"1","article-title":"Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST) [abstract O-0034]","volume":"18","author":"Van Cutsem","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122308154462900_B27","first-page":"1696","article-title":"Erlotinib\/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas","volume":"21","author":"Senderowicz","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"2021122308154462900_B28","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308154462900_B30","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMc076359","article-title":"More on severe cutaneous reaction with radiotherapy and cetuximab","volume":"357","author":"Bonner","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B31","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","article-title":"Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy","volume":"115","author":"Tejwani","year":"2009","journal-title":"Cancer"},{"key":"2021122308154462900_B32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1634\/theoncologist.2008-0149","article-title":"Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy","volume":"13","author":"Jatoi","year":"2008","journal-title":"The Oncologist"},{"key":"2021122308154462900_B33","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","article-title":"Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients","volume":"16","author":"Nardone","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308154462900_B34","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"2021122308154462900_B35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"2021122308154462900_B36","first-page":"391","article-title":"European recommendations on the use of oral antibiotics for acne","volume":"14","author":"Dreno","year":"2004","journal-title":"Eur J Dermatol"},{"key":"2021122308154462900_B37","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: A review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"suppl 1","key":"2021122308154462900_B38","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1111\/j.1610-0387.2006.06053_suppx.x","article-title":"[Systemic antibiotic therapy of acne vulgaris.]","volume":"8","author":"Ochsendorf","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"issue":"suppl 1","key":"2021122308154462900_B39","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 2","key":"2021122308154462900_B40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1054\/bjoc.2000.1757","article-title":"SOR: Project methodology","volume":"84","author":"Fervers","year":"2001","journal-title":"Br J Cancer"},{"key":"2021122308154462900_B41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"2021122308154462900_B42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1468-3083.2009.03446.x","article-title":"Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer","volume":"24","author":"Ocvirk","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122308154462900_B43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"2021122308154462900_B44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"2021122308154462900_B45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"2021122308154462900_B46","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1056\/NEJMicm050560","article-title":"Images in clinical medicine. Cetuximab-associated acneiform eruption","volume":"353","author":"Moss","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B47","first-page":"71","article-title":"Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors","volume":"32","author":"Alexandrescu","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"2021122308154462900_B48","first-page":"246","article-title":"Acneiform eruption induced by cetuximab","volume":"15","author":"Cotena","year":"2007","journal-title":"Acta Dermatovenerol Croat"},{"issue":"suppl 4","key":"2021122308154462900_B49","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1177\/17246008070221s407","article-title":"Clinical management of cutaneous toxicity of anti-EGFR agents","volume":"22","author":"Monti","year":"2007","journal-title":"Int J Biol Markers"},{"key":"2021122308154462900_B50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000106075","article-title":"Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor","volume":"20","author":"Gencoglan","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"2021122308154462900_B51","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3349\/ymj.2008.49.5.851","article-title":"Severe acneiform eruption induced by cetuximab (Erbitux)","volume":"49","author":"Lee","year":"2008","journal-title":"Yonsei Med J"},{"issue":"suppl 2","key":"2021122308154462900_B52","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1111\/j.1529-8019.2008.00233.x","article-title":"Rosaceiform eruption induced by erlotinib","volume":"21","author":"Patrizi","year":"2008","journal-title":"Dermatol Ther"},{"key":"2021122308154462900_B53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-4632.2009.03835.x","article-title":"Erlotinib-induced dermatologic side-effects","volume":"48","author":"Bovenschen","year":"2009","journal-title":"Int J Dermatol"},{"key":"2021122308154462900_B54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jaad.2008.07.057","article-title":"Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin","volume":"60","author":"Acharya","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/ejd.2010.0806","article-title":"Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab\u2014a report of 29 patients","volume":"20","author":"Katzer","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2021122308154462900_B57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.cad.0000203385.45163.76","article-title":"Aspirin reduces adverse effects of gefitinib","volume":"17","author":"Kanazawa","year":"2006","journal-title":"Anticancer Drugs"},{"key":"2021122308154462900_B58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/09537100802592692","article-title":"Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer","volume":"20","author":"Kanazawa","year":"2009","journal-title":"Platelets"},{"key":"2021122308154462900_B59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: Clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"2021122308154462900_B60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000277656","article-title":"Treatment of epidermal growth factor receptor antagonist-induced skin rash: Results of a survey among German oncologists","volume":"33","author":"Hassel","year":"2010","journal-title":"Onkologie"},{"key":"2021122308154462900_B61","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archderm.141.9.1173","article-title":"Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy","volume":"141","author":"Micantonio","year":"2005","journal-title":"Arch Dermatol"},{"key":"2021122308154462900_B62","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.08.033","article-title":"An acneiform eruption due to erlotinib: Prognostic implications and management","volume":"54","author":"Journagan","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B63","first-page":"552","article-title":"Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor","volume":"17","author":"Eames","year":"2007","journal-title":"Eur J Dermatol"},{"key":"2021122308154462900_B64","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/archdermatol.2010.170","article-title":"Papulopustular eruption associated with panitumumab","volume":"146","author":"Korman","year":"2010","journal-title":"Arch Dermatol"},{"key":"2021122308154462900_B65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3816\/CCC.2008.n.007","article-title":"Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic\/dermatologic cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"2021122308154462900_B66","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"2021122308154462900_B67","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2310\/6620.2007.06037","article-title":"Acneiform reaction to erlotinib","volume":"18","author":"Schalock","year":"2007","journal-title":"Dermatitis"},{"key":"2021122308154462900_B68","first-page":"87","article-title":"Papulo-pustular eruption during cetuximab treatment","volume":"143","author":"Satta","year":"2008","journal-title":"G Ital Dermatol Venereol"},{"key":"2021122308154462900_B69","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1468-3083.2009.03490.x","article-title":"Cetuximab-induced cutaneous toxicity","volume":"24","author":"Tomkov\u00e0","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122308154462900_B70","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"issue":"15 suppl","key":"2021122308154462900_B72","doi-asserted-by":"crossref","first-page":"A9019","DOI":"10.1200\/jco.2010.28.15_suppl.9019","article-title":"CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients","volume":"28","author":"Deplanque","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B73","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B74","first-page":"443","article-title":"[Acneiform eruptions induced by cetuximab.]","volume":"130","author":"Walon","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"2021122308154462900_B75","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaad.2006.06.034","article-title":"Treatment of gefitinib-associated folliculitis","volume":"55","author":"Matheis","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"DeWitt","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2021122308154462900_B77","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/CAD.0b013e3281ceabec","article-title":"Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer","volume":"18","author":"Boeck","year":"2007","journal-title":"Anticancer Drugs"},{"key":"2021122308154462900_B78","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.2006.09.4045","article-title":"Temporal dependence of the effect of radiation on erlotinib-induced skin rash","volume":"25","author":"Lacouture","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B79","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2010-0063","article-title":"Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: An early and a late phase of papulopustular eruptions","volume":"15","author":"Amitay-Laish","year":"2010","journal-title":"The Oncologist"},{"key":"2021122308154462900_B80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"2021122308154462900_B81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0151-9638(06)70887-0","article-title":"[Skin signs associated with epidermal growth factor inhibitors.]","volume":"133","author":"Hannoud","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"2021122308154462900_B82","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/ejd.2009.0650","article-title":"Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients","volume":"19","author":"Noronha e Menezes","year":"2009","journal-title":"Eur J Dermatol"},{"key":"2021122308154462900_B83","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B84","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","article-title":"Molecular predictors of outcome with gefitinib and docetaxel in previously treated non small cell lung cancer: Data from the randomized phase III INTEREST trial","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B86","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","article-title":"Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"24","author":"Bezjak","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B87","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","article-title":"Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"26","author":"Wheatley-Price","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B89","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.23490","article-title":"Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer","volume":"112","author":"Spigel","year":"2008","journal-title":"Cancer"},{"key":"2021122308154462900_B90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","article-title":"Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer","volume":"6","author":"Gibson","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"2021122308154462900_B91","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","article-title":"Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab","volume":"97","author":"Siena","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122308154462900_B92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3816\/CLC.2008.n.037","article-title":"An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin\/gemcitabine versus first-line cisplatin\/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: Treatment rationale and protocol dynamics of the TORCH trial","volume":"9","author":"Gridelli","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"2021122308154462900_B93","first-page":"79","article-title":"RTOG 0522: A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas","volume":"5","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122308154462900_B94","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3816\/CCC.2005.n.043","article-title":"Cancer and Leukemia Group B\/Southwest Oncology Group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma","volume":"5","author":"Venook","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"2021122308154462900_B95","first-page":"452","article-title":"CALGB\/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum","volume":"4","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122308154462900_B96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3816\/CCC.2007.n.011","article-title":"Panitumumab with irinotecan\/leucovorin\/5 fluorouracil for first line treatment of metastatic colorectal cancer","volume":"6","author":"Berlin","year":"2007","journal-title":"Clin Colorectal Cancer"},{"key":"2021122308154462900_B97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","article-title":"Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial","volume":"9","author":"Cascinu","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B98","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II\/III REAL 3 trial","volume":"28","author":"Okines","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2009.n.005","article-title":"An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors","volume":"8","author":"Stephenson","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"2021122308154462900_B100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/1078-0432.CCR-07-1509","article-title":"Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies","volume":"14","author":"Weiner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122308154462900_B101","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdn020","article-title":"Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil","volume":"19","author":"Pfeiffer","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308154462900_B102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B103","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B104","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B105","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B106","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"2021122308154462900_B107","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B108","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B109","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: A phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B110","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]","volume":"27","author":"Stewart","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B111","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3748\/wjg.v16.i25.3133","article-title":"Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial","volume":"16","author":"Ocvirk","year":"2010","journal-title":"World J Gastroenterol"},{"key":"2021122308154462900_B112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open label, single arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308154462900_B113","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B114","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B115","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1200\/JCO.2009.27.9356","article-title":"Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342","volume":"28","author":"Herbst","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B116","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/cncr.23902","article-title":"Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: A multicenter phase 2 study","volume":"113","author":"Belani","year":"2008","journal-title":"Cancer"},{"key":"2021122308154462900_B117","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","article-title":"Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B118","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B119","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bjc.6604877","article-title":"Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience","volume":"100","author":"Adams","year":"2009","journal-title":"Br J Cancer"},{"key":"2021122308154462900_B120","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/annonc\/mdm607","article-title":"A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity","volume":"19","author":"Tol","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308154462900_B121","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B122","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B123","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B124","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B125","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non small cell lung cancer (FLEX): An open label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"2021122308154462900_B126","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B127","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","article-title":"Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099","volume":"28","author":"Lynch","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B128","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2006.07.5754","article-title":"Phase II clinical trial of chemotherapy-naive patients \u226570 years of age treated with erlotinib for advanced non-small-cell lung cancer","volume":"25","author":"Jackman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B129","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","article-title":"Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer","volume":"27","author":"Mok","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.2005.04.9890","article-title":"Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126","volume":"24","author":"West","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B131","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study","volume":"27","author":"Natale","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B132","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B133","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CAD.0b013e32833123ed","article-title":"Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019","volume":"21","author":"Boeck","year":"2010","journal-title":"Anticancer Drugs"},{"key":"2021122308154462900_B134","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2007.14.4824","article-title":"Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023","volume":"26","author":"Kelly","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-09-1903","article-title":"Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy","volume":"16","author":"Lee","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308154462900_B136","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1200\/JCO.2007.15.0185","article-title":"Phase III study, V-15\u201332, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer","volume":"26","author":"Maruyama","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B137","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.2009.23.3445","article-title":"Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a west Japan Thoracic Oncology Group trial (WJTOG0203)","volume":"28","author":"Takeda","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B138","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308154462900_B139","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B140","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122308154462900_B141","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: A systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"key":"2021122308154462900_B142","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11319280-000000000-00000","article-title":"Minocycline in acne vulgaris: Benefits and risks","volume":"11","author":"Ochsendorf","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"2021122308154462900_B143","first-page":"213","article-title":"Fewer adverse effects with doxycycline than with minocycline","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"issue":"suppl 1","key":"2021122308154462900_B144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-4632.2007.03463.x","article-title":"Acne on pigmented skin","volume":"46","author":"Poli","year":"2007","journal-title":"Int J Dermatol"},{"key":"2021122308154462900_B145","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000049398","article-title":"Lymecycline and minocycline in inflammatory acne: A randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy","volume":"15","author":"Pierard-Franchimont","year":"2002","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"2021122308154462900_B146","first-page":"130","article-title":"Lymecycline in the treatment of acne: An efficacious, safe and cost-effective alternative to minocycline","volume":"13","author":"Bossuyt","year":"2003","journal-title":"Eur J Dermatol"},{"issue":"1","key":"2021122308154462900_B147","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: Efficacy and safety","author":"Garner","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"18 suppl","key":"2021122308154462900_B148","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1200\/jco.2006.24.18_suppl.18538","article-title":"Managing cutaneous side effects associated with erlotinib in head and neck cancer and non-small-lung cancer patient","volume":"24","author":"Oishi","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308154462900_B149","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","article-title":"HER1\/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum","volume":"10","author":"Perez-Soler","year":"2005","journal-title":"The Oncologist"},{"key":"2021122308154462900_B150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/CAD.0b013e32833034e1","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?","volume":"20","author":"Rukazenkov","year":"2009","journal-title":"Anticancer Drugs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2011-0365","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0365","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/4\/555\/41858981\/oncolo_17_4_555.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/4\/555\/41858981\/oncolo_17_4_555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T15:51:07Z","timestamp":1640274667000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/4\/555\/6445237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,16]]},"references-count":150,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,3,16]]},"published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0365","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,1]]},"published":{"date-parts":[[2012,3,16]]}}}